International
The BNT162b2 XBB vaccine (Pfizer-BioNTech) provided protection against COVID-19–associated hospitalisation and emergency department or urgent care visits among children 5 to 17 years of age during the 2023-2024 season, according to international researchers. The team in the US found that the vaccine had an estimated effectiveness point ranging from 63% to 73%, and they say that by vaccinating roughly 54.3 million 5-to-17-year–olds, the US could have averted approximately 3700 hospitalisations and roughly 111,000 ED or urgent care visits during the 2023-2024 respiratory virus season.
From:
About The Study: The results of this study suggest that the BNT162b2 XBB vaccine (Pfizer-BioNTech) provided protection against COVID-19–associated hospitalization and emergency department or urgent care visits among children 5 to 17 years of age during the 2023-2024 season with estimated vaccine effectiveness point estimates ranging from 63% to 73%.
Sign In
